---
title: "Molecular landscape and ELN risk stratification in acute myeloid leukemia: findings from the REFOR"
id: "medrxiv-0-molecular-landscape-and-risk-stratification-in-acute-myeloid-leukemia-insights"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-molecular-landscape-and-risk-stratification-in-acute-myeloid-leukemia-insights"
content_type: "clinical_feed_article"
specialty: "Hematology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.27.26361552v1?rss=1"
published_at: "2026-08-31T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Molecular landscape and ELN risk stratification in acute myeloid leukemia: findings from the REFOR
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-molecular-landscape-and-risk-stratification-in-acute-myeloid-leukemia-insights
- **Specialty:** [Hematology](https://medichelpline.com/clinical-feed/hematology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.27.26361552v1?rss=1)
- **Published At:** 2026-08-31T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The REFORM-AML study reports clinicopathological, genomic, and outcome data from a Danish, real-world cohort of 2,512 acute myeloid leukemia (**AML**) patients identified between 2015 and 2022. - Next-generation sequencing (**NGS**) data were available for 33.8% of patients (NGS+). - Among patients aged ≤70 years, baseline characteristics and outcomes were similar between NGS+ and NGS- groups. - In patients >70 years, a greater proportion of NGS+ patients received intensive treatment, yet survival among intensively treated older patients did not differ by NGS status. - The frequency and distribution of somatic mutations varied with age and sex; older age and male sex were associated with higher frequencies of **adverse-risk gene mutations**. - In intensively treated NGS+ patients, ELN2017 stratified 5-year overall survival (OS) at 58.4% (favorable), 43.4% (intermediate), and 28.2% (adverse); hazard ratios (HRs) versus intermediate risk were 0.63 for favorable and 1.45 for adverse. - Using ELN2022 in the same subgroup produced 5-year OS of 56.9% (favorable), 51.8% (intermediate), and 29.7% (adverse) with HRs of 0.78 and 1.86 versus intermediate. - Time-dependent comparative analysis showed **ELN2017** and **ELN2022** had comparable predictive performance for overall survival in intensively treated, NGS+ patients. - The authors conclude that intensively treated AML outcomes were comparable regardless of NGS availability, supporting the representativeness of the REFORM-AML database for the Danish AML population. - Study approvals were obtained from the North Denmark Region (IDs: 2021-011009 and 2021-197); patient consent was waived according to Danish legislation. - Data cannot be shared directly under Danish law but are available on application; funding was declared from the Danish Cancer Society. - Competing interests were reported for several authors, including consultancy/advisory roles, travel grants, speaker fees, and research funding as detailed in the manuscript.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=RcAWiu6eVvhqje_H_QwbL2sq3gilVDKG3dI6rjw1g74-1788231014.3341072-1.2.1.1-PjYZLGdzdrHatgieCj9R.bzW6b9qE3yYPMLo8JnDpsPPXgdinA173oE.IhQ_.7MB) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.27.26361552v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Molecular landscape and risk stratification in acute myeloid leukemia - insights from the real-world REFORM-AML cohort [ View ORCID Profile](http://orcid.org/0000-0002-6753-7051)Daniel Tuyet Kristensen, Rasmus Froberg Broendum, Michael Knudsen, Lykke Grubach, Claus Marcher, Birgitte Preiss, Maria Lyng Bibi, Estrid Hoegdall, Tim Poulsen, Vibe Skov, Andreas Due Oerskov, Kirsten Groenbaek, Jakob Werner Hansen, Claudia Schoellkopf, Jack Cowland, Mette Klarskov Andersen, Marianne Tang Severinsen, Christopher Vejgaard, Ole Halfdan Larsen, Soeren Vang, Martin Boegsted, Anne Stidsholt Roug doi: https://doi.org/10.64898/2026.08.27.26361552 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Daniel Tuyet Kristensen 1 Aarhus University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Daniel%2BTuyet%2BKristensen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kristensen%20DT&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADaniel%2BTuyet%2BKristensen%2B) * [ORCID record for Daniel Tuyet Kristensen](http://orcid.org/0000-0002-6753-7051 "Open in new tab") * For correspondence: dankrt@rm.dk Rasmus Froberg Broendum 2 Center for Clinical Data Science, Department of Clinical Medicine, Aalborg University and Research, Education, and Innovation, Aalborg University Hospital, Aalborg, Denmark; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rasmus%2BFroberg%2BBroendum%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Broendum%20RF&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARasmus%2BFroberg%2BBroendum%2B) Michael Knudsen 1 Aarhus University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Michael%2BKnudsen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Knudsen%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMichael%2BKnudsen%2B) Lykke Grubach 3 Aalborg University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lykke%2BGrubach%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Grubach%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALykke%2BGrubach%2B) Claus Marcher 4 Odense University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Claus%2BMarcher%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Marcher%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AClaus%2BMarcher%2B) Birgitte Preiss 4 Odense University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Birgitte%2BPreiss%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Preiss%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABirgitte%2BPreiss%2B) Maria Lyng Bibi 4 Odense University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Maria%2BLyng%2BBibi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bibi%20ML&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMaria%2BLyng%2BBibi%2B) Estrid Hoegdall 5 Herlev Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Estrid%2BHoegdall%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hoegdall%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEstrid%2BHoegdall%2B) Tim Poulsen 5 Herlev Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tim%2BPoulsen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Poulsen%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATim%2BPoulsen%2B) Vibe Skov 6 Roskilde Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vibe%2BSkov%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Skov%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVibe%2BSkov%2B) Andreas Due Oerskov 6 Roskilde Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Andreas%2BDue%2BOerskov%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Oerskov%20AD&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAndreas%2BDue%2BOerskov%2B) Kirsten Groenbaek 7 Copenhagen University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kirsten%2BGroenbaek%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Groenbaek%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKirsten%2BGroenbaek%2B) Jakob Werner Hansen 7 Copenhagen University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jakob%2BWerner%2BHansen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hansen%20JW&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJakob%2BWerner%2BHansen%2B) Claudia Schoellkopf 7 Copenhagen University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Claudia%2BSchoellkopf%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Schoellkopf%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AClaudia%2BSchoellkopf%2B) Jack Cowland 7 Copenhagen University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jack%2BCowland%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Cowland%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJack%2BCowland%2B) Mette Klarskov Andersen 7 Copenhagen University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mette%2BKlarskov%2BAndersen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Andersen%20MK&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMette%2BKlarskov%2BAndersen%2B) Marianne Tang Severinsen 3 Aalborg University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Marianne%2BTang%2BSeverinsen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Severinsen%20MT&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMarianne%2BTang%2BSeverinsen%2B) Christopher Vejgaard 1 Aarhus University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Christopher%2BVejgaard%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Vejgaard%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChristopher%2BVejgaard%2B) Ole Halfdan Larsen 1 Aarhus University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ole%2BHalfdan%2BLarsen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Larsen%20OH&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AOle%2BHalfdan%2BLarsen%2B) Soeren Vang 1 Aarhus University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Soeren%2BVang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Vang%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASoeren%2BVang%2B) Martin Boegsted 8 Aalborg University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Martin%2BBoegsted%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Boegsted%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMartin%2BBoegsted%2B) Anne Stidsholt Roug 1 Aarhus University Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Anne%2BStidsholt%2BRoug%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Roug%20AS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAnne%2BStidsholt%2BRoug%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.27.26361552v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1289374/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.27.26361552v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1289374/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.27.26361552v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1289374/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.27.26361552v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1289374/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.27.26361552v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1289374/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Large genomically annotated acute myeloid leukaemia (AML) datasets exist, but population-based contemporary cohorts remain scarce. Here we report clinicopathological, genomic, and outcome data from Danish AML patients. 2,512 AML patients were identified between 2015-2022, of whom 33.8% had available NGS data (NGS+). In patients ≤70 years, baseline characteristics and outcomes were comparable between NGS+ and NGS- groups. In patients >70 years, more NGS+ patients received intensive treatment, but survival was similar among intensively treated patients. The distribution of mutations varied significantly by age and sex, with older age and male sex exhibiting higher frequencies of adverse-risk gene mutations. In intensively treated NGS+ patients, ELN2017 stratified 5-year OS: 58.4% (favorable), 43.4% (intermediate), and 28.2% (adverse), with hazard ratios (HRs) of 0.63 (favorable) and 1.45 (adverse) relative to intermediate. ELN2022 yielded corresponding OS rates of 56.9%, 51.8%, and 29.7%, with HRs of 0.78 and 1.86. The two models had comparable predictive performance for OS in a time-dependent model. In conclusion, outcomes of intensively treated AML patients were comparable irrespective of NGS status, underscoring the representativeness of the REFORM-AML database for the Danish AML population. Age and male sex correlated with adverse-risk mutations, and both ELN2017 and ELN2022 robustly predicted survival. ### Competing Interest Statement D.T.K.: Consulting/advisory board: AbbVie, Astellas Pharma, Immedica pharma AB, Sevier; travel grants: Swedish Orphan Biovitrum; Research funding: unrestricted grant from Incyte Biosciences Nordic AB. L.G.: Speaker fee: GlaxoSmithKline. C.S.: Advisory board: Incyte Biosciences Distribution, Travel grants: Northon Healthcare Limited, Swedish Orphan Biovitrum, AbbVie, Jazz-pharmaceutical Denmark K.G.: Research Grant: Janssen, Medac . A.S.R.: Consultancy/advisory board: Daiichi Sankyo Nordics, AbbVie, Immedica, Servier, Novartis. Travel grants: Pfizer, Jazz Pharmaceuticals. All other authors declare no conflicts of interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was approved and registered the North Denmark Region (ID: 2021-011009 and 2021-197). According to Danish health care legislation, patient consent has been waived according to the approval. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Per Danish law, the data cannot be shared directly; however, they can be accessed through application. Additional information is available on request from the corresponding author. ## Funder Information Declared Danish Cancer Society, https://ror.org/03ytt7k16 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.27.26361552v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.29.26361716v1 "Heterogeneity in pre-vaccination population immunity can contribute to variability in vaccine effectiveness estimates")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.29.26361714v1 "Mapping the Health Burden of Neighbourhood Deprivation: Neurobiological Evidence Across the Life Span") Posted August 31, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.27.26361552v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/31/2026.08.27.26361552.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.27.26361552v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/31/2026.08.27.26361552.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Molecular landscape and risk stratification in acute myeloid leukemia - insights from the real-world REFORM-AML cohort Daniel Tuyet Kristensen, Rasmus Froberg Broendum, Michael Knudsen, Lykke Grubach, Claus Marcher, Birgitte Preiss, Maria Lyng Bibi, Estrid Hoegdall, Tim Poulsen, Vibe Skov, Andreas Due Oerskov, Kirsten Groenbaek, Jakob Werner Hansen, Claudia Schoellkopf, Jack Cowland, Mette Klarskov Andersen, Marianne Tang Severinsen, Christopher Vejgaard, Ole Halfdan Larsen, Soeren Vang, Martin Boegsted, Anne Stidsholt Roug medRxiv 2026.08.27.26361552; doi: https://doi.org/10.64898/2026.08.27
## Related Clinical Research

- [T lymphocytes and natural killer cells in myelodysplastic syndromes: review overview and access no](https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-t-lymphocytes-and-natural-killer-cells-in-myelodysplastic-syndromes-function.md)
- [Perturb‑seq reveals co‑regulated gene programs governing hematopoietic stem and progenitor cells](https://medichelpline.com/clinical-feed/biorxiv-16-perturb-seq-identifies-co-regulated-gene-programs-shaping-hematopoietic-stem.md)
- [Sequential conditioning for hematopoietic stem cell transplant in elderly high-risk myeloid malign](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-sequential-conditioning-in-hematopoietic-stem-cell-transplantation-in-elderly.md)
- [Vision Language Models underperform for detecting Acute Myeloid Leukemia in bone marrow smears](https://medichelpline.com/clinical-feed/medrxiv-17-vision-language-models-fail-to-reliably-detect-acute-myeloid-leukemia-in-bone.md)
- [Whole-genome sequencing identifies rare coding variants and key genes associated with acute myeloi](https://medichelpline.com/clinical-feed/medrxiv-21-prioritizing-genes-and-rare-protein-coding-variants-in-acute-myeloid-leukemia.md)

## Navigation
- [← Back to Hematology Feed](https://medichelpline.com/clinical-feed/hematology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.